Zavetox (Enzobiotics) is a scientifically validated solution for patients suffering from chronic kidney disease (CKD). Its primary purpose is to delay the need for dialysis by effectively reducing Protein Bound Uremic Toxins, specifically p Cresol Sulfate and Indoxyl Sulfate. By doing so, it not only postpones dialysis but also improves the overall Quality of Life for individuals.

Enzobiotics operates in the small intestine, strategically minimising the passage of undigested residual protein to the colon through enzymatic processes. Simultaneously, in the large intestine, it restores a balanced gut microbiome, mitigating proteolytic fermentation—a major contributor to the generation of Uremic Toxins in chronic kidney disease patients.

p Cresol Sulfate (PCS) is a protein-bound uremic toxin implicated in renal tubular damage, while Indoxyl Sulfate contributes to aortic calcification and vascular stiffness. Extensive studies confirm that these toxins play a prominent role in the progression of CKD to advanced stages and significantly contribute to mortality attributed to cardiovascular diseases.

The EETOX study on Zavetox has revealed that the Enzobiotics group maintains eGFR levels compared to a 7% decline in the Placebo group within 90 days. Patients in the Enzobiotics group experience a noteworthy enhancement in their Quality of Life. Notably, Zavetox reduces p Cresol Sulfate and Indoxyl Sulfate, mitigating the risk of CKD progression by 68% (PCS) and 75% (IS). Additionally, Enzobiotics significantly alleviates Uremic Symptoms, showcasing its comprehensive benefits in preserving kidney function and enhancing the overall well-being of individuals.

Explore the comprehensive scientific backing for Enzobiotics through the EETOX Study and Pre-clinical Trials here (Refer to the link given above).

What accreditations does the study hold?

Elevating pharmaceutical standards, Mylin Biotech has garnered prestigious accolades, marking a paradigm shift in the industry. Here are some of our notable achievements:

• Pioneering pharmaceutical research-oriented company from India
• Presented the first Randomized Control Trial (RCT) at the American Society of Nephrology in October 2020
• Recognized for excellence with a nomination from the Clinical Journal Society of America in the best clinical trial category
• EETOX study published in Nutrients, a high-impact factor journal with a rating of 6.7
• Groundbreaking achievements establishing Indian Nephrology at the forefront globally
• Setting a new precedent for excellence in the pharmaceutical landscape

In a word, yes. Preclinical studies unequivocally demonstrate that Enzobiotics outperforms probiotics, significantly reducing creatinine, blood urea nitrogen, and enhancing protein levels.

Zavetox is classified as safe under the Generally Recognized as Safe (GRAS) category. A minimal percentage of patients might encounter transient symptoms like nausea and bloating, lasting no more than 2-3 days, allowing for continued use. In case of any allergic reactions to the labeled ingredients, it is advisable to discontinue the therapy.

For optimal effectiveness, consume each Enzobiotics capsule either 10 minutes before or immediately after a meal.

Enzobiotics come carefully packaged in boxes, each containing 28 capsules.

To maintain its efficacy, it is recommended to store the product in a refrigerator at temperatures between 2-8 degrees Celsius. In case of brief periods outside the refrigerator, up to 2-3 days (avoiding exposure to sunlight), the product remains stable.

CKD is a multifactorial disease. Zavetox should be complemented with other medications prescribed by a Nephrologist for an effective management approach.

For optimal effectiveness, consume each Enzobiotics capsule either 10 minutes before or immediately after a meal.

Zavetox has sought patent protection in 56 countries.